Skip to main content

Table 1 Characteristics of the study sample

From: Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

  MCI subgroup p value
MCINon+ MCIAβ+ MCIAβ+T+ MCIAll+ MCIT+
N 111 45 119 145 49  
Age (years) 71.29 (7.83) 74.78 (6.59) 74.25 (7.06) 72.68 (7.40) 71.57 (9.00) 0.010
Education (years) 16.54 (2.70) 16.29 (3.07) 16.13 (2.77) 15.97 (2.83) 15.92 (2.86) 0.468
MMSE 28.13 (1.70) 27.64 (1.79) 27.42 (1.88) 26.93 (1.87) 27.92 (1.78) <0.001
Sex (male:female) 67:44 34:11 78:41 73:72 29:20 0.020
APOE ε4 carriers (%) 21.62 42.22 62.18 77.93 26.53 <.001
CSF Aβ42 (pg/ml) 232.59 (30.25) 140.81 (26.14) 132.81 (23.70) 134.98 (20.96) 232.93 (30.24) <0.001
CSF Aβ42 negative/borderline/positive for AD 87/24/0 0/0/45 0/0/119 0/0/145 39/10/0 <0.001
CSF p-Tau (pg/ml) 18.63 (4.44) 20.36 (4.45) 43.66 (16.00) 58.41 (2.53) 41.77 (13.58) <0.001
CSF p-Tau negative/borderline/positive for AD 57/54/0 18/27/0 0/2/117 0/0/145 0/0/49 <0.001
CSF t-Tau (pg/ml) 50.66 (18.12) 55.53 (17.28) 78.37 (18.06) 158.09 (46.47) 74.86 (34.40) <0.001
CSF t-Tau negative/borderline/positive for AD 106/5/0 42/3/0 59/58/2 0/0/145 29/15/5 <0.001
Follow-up period (months) 32.22 (23.34) 32.53 (23.50) 30.81 (22.34) 29.96 (21.01) 32.02 (11.64) 0.350
Dementia due to AD vs no dementia at follow-up 14:97 14:31 43:76 80:65 8:41 <0.001
  1. Data presented as mean (standard deviation) or frequencies
  2. AD Alzheimer’s disease, MCI mild cognitive impairment, APOE apolipoprotein E, MMSE Mini-Mental State Examination, CSF cerebrospinal fluid, Aβ42 amyloid-beta 1–42, p-Tau tau phosphorylated at threonine 181, t-Tau total tau, MCI Non+ MCI without positive CSF biomarkers, MCI Aβ+ MCI with positive Aβ42 and negative or borderline p-Tau and t-Tau, MCI Aβ+T+ MCI with positive Aβ42 and positive t-Tau or p-Tau, MCI All+ MCI with Aβ42 and both t-Tau and p-Tau positive, MCI T+ MCI with negative or borderline Aβ42 and at least p-Tau or t-Tau positive